Moderna/Merck's Personalized mRNA Cancer Vaccine Hits First-Ever Positive Phase 3
ChrisGPT · x · 2026-08-20
Moderna and Merck's individualized neoantigen therapy just got the first positive Phase 3 result ever for a personalized neoantigen therapy and an mRNA-based cancer treatment. The pipeline: sequence each patient's tumor, identify unique mutations, algorithmically select up to 34 neoantigens, then manufacture a personalized mRNA treatment teaching the patient's immune system to recognize their cancer, combined with Keytruda which takes the brakes off the immune response.
Evidence is much stronger than Phase 2: that study had only 157 patients but showed 49% lower risk of recurrence or death and 59% lower risk of distant metastasis/death at five years. Phase 3 tested 1,137 patients and still hit both recurrence-free survival and distant metastasis-free survival endpoints vs Keytruda alone; exact effect size not yet published.
More from Research
- Dev critiques compiling fast programs into slow neural nets: fun, but not useful — ctjlewis · 2026-10-16
- New paper uses revealed-preference methods to unpack why AI agents cooperate — brwilder · 2026-10-16
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16
- MIT's C-GMT gives humanoid robots whole-body compliance without sacrificing motion tracking — MIT_CSAIL · 2026-10-16